TMG (Betaine): Methyl Donor for Homocysteine, Performance & Liver — A Research-Backed Guide

What is TMG (betaine)?

TMG stands for trimethylglycine — glycine with three methyl groups attached to its nitrogen atom. It is also called betaine or glycine betaine (to distinguish it from other betaines like betaine HCl, which is a completely different compound). The name "betaine" comes from sugar beets (Beta vulgaris), the original commercial source — today, betaine is also extracted from wheat germ, spinach, and quinoa.

Critical nomenclature warning: "Betaine" can refer to TMG (trimethylglycine, the methyl donor) or to "betaine HCl" (betaine hydrochloride, a stomach acid supplement). These are entirely different molecules with different mechanisms, different uses, and different safety profiles. Always verify which betaine your supplement contains. This page covers TMG/trimethylglycine only.

TMG's role in one-carbon metabolism

TMG is a central player in one-carbon metabolism — the biochemical network that transfers single-carbon units (methyl groups) for DNA methylation, neurotransmitter synthesis, creatine production, and dozens of other reactions. TMG's specific role is as a substrate for betaine-homocysteine methyltransferase (BHMT), which transfers a methyl group from TMG to homocysteine, converting it to methionine. In this reaction:

• TMG (3 methyl groups) → DMG (dimethylglycine, 2 methyl groups) → sarcosine → glycine
• Homocysteine (elevated → cardiovascular risk) → methionine (re-enters the methyl cycle)

This reaction is a parallel pathway to the folate-dependent remethylation of homocysteine (via methionine synthase and vitamin B12). Both pathways converge on the same endpoint — reducing plasma homocysteine — which is why TMG and folate have additive effects on homocysteine reduction, and why both are relevant when homocysteine is elevated.

BHMT is highly expressed in the liver and kidneys, which is why TMG's homocysteine-lowering effect is primarily hepatic. TMG also functions as an osmolyte — a molecule that protects cells from osmotic stress by accumulating intracellularly without disrupting enzyme function. This osmolyte role is particularly important in hepatocytes, muscle cells, and renal tubular cells during dehydration or exercise.

Dietary sources

TMG/betaine is found in:

• Wheat germ and wheat bran (~1,000–1,400 mg/100 g) — the richest source
• Quinoa (~390 mg/100 g dry)
• Spinach (~600–700 mg/100 g)
• Beets and sugar beets (~120–280 mg/100 g)
• Shellfish (shrimp, oysters): 200–400 mg/100 g
• Rye bread, whole grains: moderate amounts

Average Western dietary intake is approximately 1–2.5 g/day from food. Supplemental doses typically start where dietary intake ends and go much higher for therapeutic purposes.

Evidence-based benefits of TMG supplementation

1. Homocysteine reduction: well-established evidence

The most robustly documented effect of TMG supplementation is lowering plasma homocysteine. Elevated homocysteine (>15 µmol/L) is associated with cardiovascular disease, stroke, cognitive decline, and neural tube defects — though debate continues about whether homocysteine is causal or a biomarker.

The key clinical reference is Olthof et al. (2003), a placebo-controlled crossover RCT in healthy adults with mildly elevated homocysteine. Supplementing 4 g/day TMG for 6 weeks reduced fasting homocysteine by approximately 1.1 µmol/L from baseline. Notably, TMG reduced homocysteine but simultaneously raised LDL cholesterol and total cholesterol by a small but statistically significant amount — an important tradeoff to consider. Multiple subsequent meta-analyses have confirmed homocysteine reduction of 0.5–2 µmol/L at doses of 2–6 g/day, with the response larger in individuals with higher baseline homocysteine.

TMG's homocysteine effect is additive with folate (vitamin B9), as the two work via parallel pathways. People with mildly elevated homocysteine may benefit from optimizing both folate status and adding TMG if folate alone is insufficient.

2. Athletic performance and body composition (Cholewa et al. 2013)

The most-cited performance RCT is Cholewa et al. (2013), published in the Journal of the International Society of Sports Nutrition. In this 6-week double-blind RCT in resistance-trained men:

• 2.5 g/day betaine anhydrous significantly increased bench press and squat strength versus placebo
• TMG group showed greater lean mass gain and arm cross-sectional area compared to placebo
• No significant difference in fat mass loss

The proposed mechanisms include TMG's role as a methyl donor for creatine synthesis (creatine is the largest consumer of methyl groups in the body), improved osmotic protection of muscle cells during exercise, and possible IGF-1 modulation. A 2013 meta-analysis and subsequent replication studies show modest but consistent strength and body composition benefits at 2.5 g/day. Effect sizes are smaller than creatine monohydrate but the compounds are complementary (TMG supports creatine biosynthesis).

3. Liver protection via osmolyte function

Hepatocyte protection is one of TMG's oldest known functions. Betaine is a key osmolyte in liver cells, and its depletion has been linked to liver injury in models of alcoholic and non-alcoholic fatty liver disease (NAFLD/NASH). The mechanism involves:

• Osmotic protection of hepatocytes under lipid-loading stress
• Methyl donor support for phosphatidylcholine synthesis (needed for hepatic VLDL export — a key step in fat export from the liver)
• Indirect reduction of homocysteine-mediated endoplasmic reticulum stress in hepatocytes

A 2009 RCT (Abdelmalek et al.) in NAFLD patients found that 20 g/day betaine for 12 months modestly improved hepatic steatosis and some liver enzyme markers, though not all endpoints reached significance. A 2016 meta-analysis found mixed results across liver disease populations, with more consistent benefits in alcoholic liver disease than NASH. At common supplemental doses (2–4 g/day), liver-protective effects are likely present but of uncertain magnitude in humans without pre-existing liver disease.

4. Cardiovascular support via homocysteine (mediated benefit)

The cardiovascular benefit case for TMG is primarily mediated through homocysteine reduction. Whether lowering homocysteine with B vitamins or TMG reduces cardiovascular events remains controversial — large B-vitamin trials (HOPE-2, VISP) showed homocysteine reduction did not translate to cardiovascular event reduction in secondary prevention populations. The current view is that homocysteine may be a biomarker rather than a causal factor, and that TMG's value may be greater in primary prevention or in populations with genetic hyperhomocysteinemia (e.g., MTHFR variants).

The TMAO controversy: what you need to know

TMAO (trimethylamine N-oxide) is produced when gut bacteria metabolize trimethylamine-containing compounds — including choline, carnitine, and TMG — and the resulting TMA is oxidized in the liver. Elevated plasma TMAO has been associated with cardiovascular disease risk in multiple large observational studies, most prominently by Cho et al. (2017, NEJM) and the Cleveland Clinic group (Tang et al.).

Because TMG contains three methyl groups, gut bacteria can potentially use it as a TMA precursor, raising plasma TMAO. Key points to understand:

• The effect is highly variable: TMAO production from TMG depends heavily on individual gut microbiome composition. Some individuals are "high TMAO producers" and some are not. You cannot predict your response without testing.
• The magnitude from TMG appears smaller than from carnitine or choline: Not all methyl donors raise TMAO equally. Available data suggest TMG raises TMAO less than equivalent doses of carnitine or phosphatidylcholine, but direct comparative studies are limited.
• Causality is unresolved: TMAO may be a biomarker of gut dysbiosis, diet quality, or renal function rather than a direct cardiovascular toxin. Interventional data are lacking.
• Practical implication: People with existing cardiovascular disease, high cardiovascular risk, or known gut dysbiosis should discuss TMG supplementation with their physician before starting. Healthy individuals at low cardiovascular risk can weigh the homocysteine benefit against the theoretical TMAO risk, noting that the evidence for meaningful harm at typical supplemental doses is not established.

TMG supplement forms compared

There are only two forms of TMG that matter for supplementation, plus the critical impostor to avoid confusing:

How much TMG should you take?

There is no RDA for TMG. Clinical and functional guidance by use case:

• Homocysteine reduction: 2,000–4,000 mg/day — the Olthof et al. trial used 4 g/day and showed reliable reduction; lower doses (2 g/day) show smaller effects
• Athletic performance and body composition: 2,500 mg/day — the Cholewa et al. 2013 protocol; consistent with most sports-nutrition RCTs
• Liver health / NASH support: Research trials used 10,000–20,000 mg/day, but these are pharmacological doses; typical supplemental use at 2–4 g/day has theoretical but not clinical-RCT support at those doses
• General methylation support / longevity stacks: 500–1,500 mg/day — often combined with folate, B12, and sometimes SAMe
• Maximum studied dose: ~6,000 mg/day in clinical trials without serious adverse effects

Timing: Split the dose across two meals (e.g., with breakfast and with dinner) to reduce peak GI load and to minimize any single peak in TMAO production. TMG does not need to be taken at a specific time relative to exercise for performance effects — daily total dose matters more than acute timing.

Stacking: TMG works synergistically with folate (B9) and vitamin B12 for homocysteine reduction (parallel pathways). With creatine monohydrate for performance (TMG supports endogenous creatine synthesis; exogenous creatine adds to the pool). Discuss with your clinician before combining with SAMe, which also acts as a methyl donor — the total methylation push can occasionally cause overmethylation symptoms in sensitive individuals.

Safety and side effects

TMG has a generally favorable safety profile at typical supplemental doses. It is classified as GRAS (Generally Recognized as Safe) by the FDA when used as a food ingredient.

Common side effects

• GI upset — the most common issue; nausea, diarrhea, or stomach discomfort at high single doses (>3 g at once); resolved by splitting doses across meals
• Body odor or fishy smell — in a minority of users, TMG metabolism produces TMA (the fishy-smell precursor to TMAO); more common in people with trimethylaminuria (fish odor syndrome) or gut dysbiosis
• LDL cholesterol increase — Olthof et al. 2003 found modest LDL increases (+0.3 mmol/L) with 4 g/day; not universally replicated but worth monitoring in those with elevated baseline LDL

TMAO and cardiovascular risk signal

As described in the TMAO section, there is an unresolved theoretical cardiovascular risk from TMAO production. This is not established as a harm at typical supplemental doses, but it warrants ongoing attention and physician discussion for high-risk individuals.

Pregnancy and breastfeeding

TMG (betaine) is found in many foods and is not considered harmful at dietary intake levels. High-dose supplementation in pregnancy has not been adequately studied; discuss with your OB before supplementing above dietary amounts. TMG's folate-synergistic role in homocysteine reduction is relevant for pregnancy health, but ensure adequate folate is the priority.

Drug and nutrient interactions

Methotrexate — clinically important

This is the key drug interaction for TMG. Methotrexate (used for rheumatoid arthritis, psoriasis, and cancer) works as a folate antagonist — it blocks the folate pathway enzymes, including those involved in one-carbon metabolism and homocysteine re-methylation. TMG, by providing an alternative route to re-methylate homocysteine (via BHMT rather than the folate pathway), may theoretically reduce the antifolate efficacy of methotrexate. This could reduce methotrexate's therapeutic effect in cancer treatment contexts.

Practical rule: People taking methotrexate for any indication should discuss TMG supplementation with their prescribing physician or oncologist before starting. Do not supplement without this conversation.

Folate (vitamin B9) — synergistic (desired)

TMG and folate reduce homocysteine via parallel, complementary pathways. For people with elevated homocysteine, optimizing both folate (and B12, which folate-pathway remethylation also requires) alongside TMG produces larger reductions than either alone. This is a beneficial interaction — not a concern — but monitor that folate status is optimal before assuming TMG alone is sufficient.

Vitamin B12 — indirectly synergistic

The folate-pathway homocysteine remethylation (methionine synthase) requires B12 as a cofactor. In B12-deficient individuals, folate cannot efficiently reduce homocysteine — but TMG's BHMT pathway is B12-independent. This makes TMG theoretically more useful than folate alone in B12-deficient individuals, though B12 deficiency itself must also be treated.

Anticoagulants (Warfarin, etc.) — monitor

TMG affects homocysteine and methionine metabolism, which influences coagulation factor synthesis indirectly. There are no documented direct pharmacokinetic interactions with Warfarin, but anyone on anticoagulation therapy should inform their prescriber about any new supplement additions and have INR monitored appropriately.

Creatine — synergistic for performance

Creatine biosynthesis is the largest consumer of methyl groups from SAMe in the body. TMG, by donating methyl groups that eventually contribute to methionine (a SAMe precursor), may support creatine biosynthesis. Stacking TMG with creatine monohydrate is common in sports nutrition and is mechanistically rational, though research specifically on the combination is limited.

Who might benefit — and who shouldn't bother

Frequently asked questions

Related ingredients and articles